When responding to outbreaks of viral disease, public health officials are often challenged...
- Vaccine development: the need for speed
- Lack of CMO availability threatens cell and gene therapy development
- Novaliq’s NovaTears+Omega-3 represents the first-in-class omega-3-containing eye drop for evaporative dry eye
- Surprisingly good Phase II results for ibudilast in progressive MS
- Tenapanor likely to makes waves in IBS-C space
Paradigm Shift Regarding API and Formulation Components
This whitepaper will provide an introduction to high-purity carbohydrates often used for applications such as stabilisation, modulation, and cryopreservation, comparing the old paradigm that formulation components are inactive ingredients with limited functionality with the new paradigm, which suggests these components play a significant role in therapeutic stability, quality, potency, immunogenicity, and bioavailability.
Characterising Liposomes using Multi-Angle DLS
Liposomes are nowadays frequently used as drug delivery systems, and as such requires that they are well characterised for manufacturing and batch release. This characterisation includes their size and size distribution.
JYNARQUE™ (tolvaptan) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
JYNARQUE™ (tolvaptan) is indicated for the treatment of autosomal dominant polycystic kidney disease (ADPKD).
Malvern Panalytical to Showcase New X-Ray Diffraction Concept at EPDIC16
This year’s European Powder Diffraction Conference (EPDIC16) is the stage for Malvern Panalytical’s new Empyrean platform, an instrument that redefines the concept of multipurpose X-ray diffraction.
Zepatier for the Treatment of Chronic Hepatitis C Genotype 1 and 4 Infection
Zepatier is a once-daily oral medicine comprising 50mg of non-structural protein 5A (NS5A) replication complex inhibitor elbasvir and 100mg of NS3/4A protease inhibitor grazoprevir.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.